The accompanying concurrent mutations clearly provide an impact on recurrence in resected EGFR-mutated lung adenocarcinoma as the EGFR- mutated lung adenocarcinoma with more concurrent mutations had poorer response rate to EGFR-TKIs in advanced stages [12,13]. The gene discussed is EGFR; the disease is lung adenocarcinoma.